However, adding the neoadjuvant PAN-PI3K inhibitor buparlisib to trastuzumab and paclitaxel in the NeoPHOEBE phase II clinical trial was not feasible to improve pathological complete response (pCR) in patients with HER2-positive primary breast cancer. Here, ERBB2 is linked to breast cancer.